Korea Overhauls Generic Drug Rules To Enhance Pharma’s Responsibility, Competitiveness
Executive Summary
Following the worldwide generic valsartan quality woes, South Korea moves to improve the quality of generics and will eventually scrap joint bioequivalence tests, while implementing effective price cuts to later products to curb excessive competition and improve pharma firms’ responsibility for their drugs.